BD BBL™ Sensi-Disc™ Cefoxitin 30 µg 231591Recalls & reported problems
Becton, Dickinson And Company · BD BBL™ Sensi-Disc™ Cefoxitin 30 µg · Class 2
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 30382902315910), received between Jun 30, 2021 and Jul 1, 2021 — classified as 2 malfunctions.
The most frequently reported specific device problem is “Device Markings/Labelling Problem” (2 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Device Markings/Labelling Problem2
Patient problems
- No Clinical Signs, Symptoms or Conditions2
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
MalfunctionJul 1, 2021Device Markings/Labelling Problem; Device Markings/Labelling Problem
IT WAS REPORTED THAT WHILE USING 5 BD BBL¿ SENSI-DISC¿ CEFOXITIN - 30 G A MIX OF PRODUCT TYPES IN THE PACKAGE WAS OBSERVED BY THE LABORATORY PERSONNEL. THERE WAS NO REPORT OF PATIENT IMPACT. THE FOLLOWING INFORMATION WAS PROVIDED BY THE INITIAL REPORTER: "PACKAGING WITH PRODUCT 231591 - CARTRIDGES WITH 231590 INSIDE;".
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 12104005 ↗MalfunctionJun 30, 2021Device Markings/Labelling Problem; Device Markings/Labelling Problem
IT WAS REPORTED THAT THERE WAS A MIX OF PRODUCT BD BBL¿ SENSI-DISC¿ CEFOXITIN - 30 ¿G, PACKAGING IS FOR PART# 231591, HOWEVER, THE CARTRIDGES WERE PART# 231590. PRODUCT WAS USED, HOWEVER, THERE WAS NO REPORT OF PATIENT IMPACT. THE FOLLOWING INFORMATION WAS PROVIDED BY THE INITIAL REPORTER: PACKAGING WITH PRODUCT 231591 - CARTRIDGES WITH 231590 INSIDE; 5 X À 10 CARTRIDGES. PRODUCT USED.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 12095126 ↗
Other SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL devices
- BD BBL Sensi-Disc Ampicillin 2 ug 231263Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL2 recalls0 reports
- BD BBL™ Sensi-Disc™ Ciprofloxacin 5 µg 231658Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall2 reports
- BD BBL™ Sensi-Disc™ Piperacillin/Tazobactam 100/10 µg 231691Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Ceftazidime 30 µg 231633Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Levofloxacin 5 µg 231706Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Cefepime 30 µg 231696Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall1 report
- BD BBL™ Sensi-Disc™ Chloramphenicol 30 µg 231274Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall0 reports
- BD BBL™ Sensi-Disc™ Cefotaxime 30 µg 231607Becton, Dickinson And Company · SUSCEPTIBILITY TEST DISCS, ANTIMICROBIAL1 recall0 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page